BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19064921)

  • 1. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.
    Pekarsky Y; Palamarchuk A; Maximov V; Efanov A; Nazaryan N; Santanam U; Rassenti L; Kipps T; Croce CM
    Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19643-8. PubMed ID: 19064921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.
    Sivina M; Hartmann E; Vasyutina E; Boucas JM; Breuer A; Keating MJ; Wierda WG; Rosenwald A; Herling M; Burger JA
    Leukemia; 2012 Aug; 26(8):1812-20. PubMed ID: 22460735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.
    Motiwala T; Zanesi N; Datta J; Roy S; Kutay H; Checovich AM; Kaou M; Zhong Y; Johnson AJ; Lucas DM; Heerema NA; Hagan J; Mo X; Jarjoura D; Byrd JC; Croce CM; Jacob ST
    Blood; 2011 Dec; 118(23):6132-40. PubMed ID: 22001392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies.
    Gaudio E; Spizzo R; Paduano F; Luo Z; Efanov A; Palamarchuk A; Leber AS; Kaou M; Zanesi N; Bottoni A; Costinean S; Rassenti LZ; Nakamura T; Kipps TJ; Aqeilan RI; Pekarsky Y; Trapasso F; Croce CM
    Blood; 2012 Jan; 119(1):180-7. PubMed ID: 22065599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL).
    Palamarchuk A; Yan PS; Zanesi N; Wang L; Rodrigues B; Murphy M; Balatti V; Bottoni A; Nazaryan N; Alder H; Rassenti L; Kipps TJ; Freitas M; Croce CM; Pekarsky Y
    Proc Natl Acad Sci U S A; 2012 Feb; 109(7):2555-60. PubMed ID: 22308499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
    Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
    Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.
    Efanov A; Zanesi N; Nazaryan N; Santanam U; Palamarchuk A; Croce CM; Pekarsky Y
    Leukemia; 2010 May; 24(5):970-5. PubMed ID: 20357824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model.
    Zanesi N; Balatti V; Riordan J; Burch A; Rizzotto L; Palamarchuk A; Cascione L; Lagana A; Dupuy AJ; Croce CM; Pekarsky Y
    Blood; 2013 May; 121(21):4355-8. PubMed ID: 23591791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of the RelB NF-kappaB subunit by the cytomegalovirus IE1 protein is mediated via Jun kinase and c-Jun/Fra-2 AP-1 complexes.
    Wang X; Sonenshein GE
    J Virol; 2005 Jan; 79(1):95-105. PubMed ID: 15596805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
    Pekarsky Y; Santanam U; Cimmino A; Palamarchuk A; Efanov A; Maximov V; Volinia S; Alder H; Liu CG; Rassenti L; Calin GA; Hagan JP; Kipps T; Croce CM
    Cancer Res; 2006 Dec; 66(24):11590-3. PubMed ID: 17178851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.
    Bichi R; Shinton SA; Martin ES; Koval A; Calin GA; Cesari R; Russo G; Hardy RR; Croce CM
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6955-60. PubMed ID: 12011454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
    Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
    Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
    Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
    Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.
    Balatti V; Rizzotto L; Miller C; Palamarchuk A; Fadda P; Pandolfo R; Rassenti LZ; Hertlein E; Ruppert AS; Lozanski A; Lozanski G; Kipps TJ; Byrd JC; Croce CM; Pekarsky Y
    Proc Natl Acad Sci U S A; 2015 Feb; 112(7):2169-74. PubMed ID: 25646413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state.
    Herling M; Patel KA; Khalili J; Schlette E; Kobayashi R; Medeiros LJ; Jones D
    Leukemia; 2006 Feb; 20(2):280-5. PubMed ID: 16341048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic alterations in a murine model for chronic lymphocytic leukemia.
    Chen SS; Sherman MH; Hertlein E; Johnson AJ; Teitell MA; Byrd JC; Plass C
    Cell Cycle; 2009 Nov; 8(22):3663-7. PubMed ID: 19901553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.
    DiLillo DJ; Weinberg JB; Yoshizaki A; Horikawa M; Bryant JM; Iwata Y; Matsushita T; Matta KM; Chen Y; Venturi GM; Russo G; Gockerman JP; Moore JO; Diehl LF; Volkheimer AD; Friedman DR; Lanasa MC; Hall RP; Tedder TF
    Leukemia; 2013 Jan; 27(1):170-82. PubMed ID: 22713648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.
    Öztürk S; Paul Y; Afzal S; Gil-Farina I; Jauch A; Bruch PM; Kalter V; Hanna B; Arseni L; Roessner PM; Schmidt M; Stilgenbauer S; Dietrich S; Lichter P; Zapatka M; Seiffert M
    Leukemia; 2022 Feb; 36(2):464-475. PubMed ID: 34417556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
    Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
    Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.